Some parts of the portal may cause error messages or display incorrectly due to the transition to a new provider of trading data

FUSN - Fusion Pharmaceuticals Inc.

IEX Last Trade
21.555
21.555   100.000%

Share volume: 0
Last Updated: Mon 03 Jun 2024 08:15:20 PM CEST
Biological Product (except Diagnostic) Manufacturing : -4.32%

PREVIOUS CLOSE
CHG
CHG%
N/A
0.00
0.00%
5D - 1M - 3M - 1Y - 3Y - 5Y - 10Y - 15Y
Overview Charts Financials Fundamental analysis Historical prices Events Documents Notes Dividends
Fundamental analysis
17%
Profitability 0%
Dept financing 23%
Liquidity 75%
Performance 18%
Company vs Stock growth
vs
+ Add row to compare
Performance
5 Days
0   0%
1 Month
0   0%
3 Months
0   0%
6 Months
0   0%
1 Year
137.33%
2 Year
640.55%
Key data
Stock price
$21.56
P/E Ratio 
0.00
DAY RANGE
N/A - N/A
EPS 
$0.00
52 WEEK RANGE
$8.34 - $21.60
52 WEEK CHANGE
$124.25
MARKET CAP 
207.988 M
YIELD 
N/A
SHARES OUTSTANDING 
68.870 M
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
N/A
BETA 
0.54
PUBLIC FLOAT 
$0
AVERAGE 10 VOLUME 
N/A
AVERAGE 30 VOLUME 
N/A
Company detail
CEO: John Valliant
Region: US
Website: fusionpharma.com
Employees: 90
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Biological Product (except Diagnostic) Manufacturing
Sector: Manufacturing

Fusion Pharmaceuticals Inc. focuses on developing radiopharmaceuticals as precision medicines. Its lead product candidate is FPI-1434 that is in Phase 1 clinical trials as a monotherapy in patients with solid tumors expressing insulin-like growth factor 1 receptor.

Recent news